Telesis Bio, Inc. (TBIO)
USD 0.49
(-7.55%)
USD 0.49
(-7.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -35.15 Million USD | 24.38% |
| 2022 | -46.48 Million USD | -31.41% |
| 2021 | -35.37 Million USD | -116.21% |
| 2020 | -16.36 Million USD | -134.53% |
| 2019 | -6.97 Million USD | 93.22% |
| 2018 | -102.96 Million USD | -30.45% |
| 2017 | -78.92 Million USD | -195.62% |
| 2016 | -26.69 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.52 Million USD | -39.87% |
| 2024 Q2 | -10.47 Million USD | -22.92% |
| 2023 Q3 | -10.12 Million USD | -27.05% |
| 2023 Q2 | -7.96 Million USD | 27.39% |
| 2023 Q4 | -6.09 Million USD | 39.81% |
| 2023 FY | -35.15 Million USD | 24.38% |
| 2023 Q1 | -10.97 Million USD | -39.16% |
| 2022 FY | -46.48 Million USD | -31.41% |
| 2022 Q1 | -12.86 Million USD | -6.33% |
| 2022 Q4 | -7.88 Million USD | 29.93% |
| 2022 Q3 | -11.25 Million USD | 22.34% |
| 2022 Q2 | -14.48 Million USD | -12.63% |
| 2021 FY | -35.37 Million USD | -116.21% |
| 2021 Q1 | -6.26 Million USD | -21.16% |
| 2021 Q2 | -7.57 Million USD | -20.88% |
| 2021 Q4 | -12.09 Million USD | -28.13% |
| 2021 Q3 | -9.44 Million USD | -24.68% |
| 2020 Q1 | -3.59 Million USD | 88.42% |
| 2020 Q2 | -3.29 Million USD | 8.32% |
| 2020 Q3 | -4.3 Million USD | -30.46% |
| 2020 Q4 | -5.17 Million USD | -20.23% |
| 2020 FY | -16.36 Million USD | -134.53% |
| 2019 Q4 | -31.03 Million USD | -46.21% |
| 2019 FY | -6.97 Million USD | 93.22% |
| 2019 Q3 | -21.22 Million USD | 23.73% |
| 2019 Q2 | -27.83 Million USD | 17.37% |
| 2019 Q1 | -33.68 Million USD | -420.14% |
| 2018 Q1 | -22.31 Million USD | 9.12% |
| 2018 Q2 | -29 Million USD | -29.99% |
| 2018 Q3 | -45.17 Million USD | -55.74% |
| 2018 Q4 | -6.47 Million USD | 85.66% |
| 2018 FY | -102.96 Million USD | -30.45% |
| 2017 FY | -78.92 Million USD | -195.62% |
| 2017 Q1 | -14.8 Million USD | 0.0% |
| 2017 Q2 | -18.8 Million USD | -27.0% |
| 2017 Q3 | -20.76 Million USD | -10.43% |
| 2017 Q4 | -24.55 Million USD | -18.24% |
| 2016 FY | -26.69 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acutus Medical, Inc. | -14.36 Million USD | -144.76% |
| Biotricity, Inc. | -8.82 Million USD | -298.153% |
| Cell MedX Corp. | -313.43 Thousand USD | -11114.625% |
| Dynatronics Corporation | -2.27 Million USD | -1446.382% |
| Nemaura Medical Inc. | -9.59 Million USD | -266.328% |
| PetVivo Holdings, Inc. | -10.62 Million USD | -230.938% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -1584.196% |
| Sonendo, Inc. | -57.74 Million USD | 39.127% |
| Talis Biomedical Corporation | -66.81 Million USD | 47.392% |
| Viveve Medical, Inc. | -21.55 Million USD | -63.086% |